The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment by harnessing the immune system to target and eliminate cancer cells.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...

China: A recent case-control observational study has raised concerns about developing proteinuria in patients undergoing ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

The following is a summary of “An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma,” ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

Researchers investigated immune-related adverse effects and characteristics that may predict their incidence in patients receiving ICIs for gastrointestinal cancers.

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.